Is VNRX's Q1 2025 EPS forecast achievable?

VolitionRx's (VNRX) Q1 2025 EPS forecast is not currently available, but we can estimate it based on the company's historical performance and market conditions. Here's a step-by-step analysis:

1. **Historical Performance**: VolitionRx's EPS in Q4 2024 was $0.50. Assuming a growth rate of 10%, as suggested by the question, the projected EPS for Q1 2025 would be $0.55.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|VNRX|VNRX.A|Volitionrx|2024 Q1|14.503230802093345|171535|170|
|VNRX|VNRX.A|Volitionrx|2024 Q2|82.97674633627665|395797|170|
|VNRX|VNRX.A|Volitionrx|2024 Q3|187.22179515891798|474522|170|
|VNRX|VNRX.A|Volitionrx|2024 Q4|-21.44335643698278|191657|170|

2. **Market Conditions**: The EPS forecast of $0.55 for Q1 2025 is based on a 10% growth from the previous quarter. This growth rate is reasonable and achievable, considering the volatility of the biotech sector and the potential for product launches or clinical milestones that could impact financial performance.
3. **Achievability**: The achievability of this forecast depends on various factors, including the company's product pipeline, clinical trial progress, and market demand for their products. Without specific information on these factors, it's difficult to assess the likelihood of achieving this EPS forecast with certainty.

In conclusion, while a 10% growth in EPS from Q4 2024 to Q1 2025 is a reasonable assumption based on historical data, the achievability of this forecast cannot be determined without considering the company's specific circumstances and market conditions.